Where does Nexstim Oyj rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Nexstim Oyj ranks #29,594 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Nexstim Oyj hold?

Nexstim Oyj holds 9 US utility patents granted between 2017 and 2024, spanning 5 technology areas.

What is Nexstim Oyj's Innovation Score?

Nexstim Oyj has an Innovation Score of 29.6 out of 100 (31st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Nexstim Oyj focus on?

Nexstim Oyj's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 9 patents, ranking #407 of 1,943 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Nexstim Oyj's patent grant rate increasing or decreasing?

Nexstim Oyj's recent grant velocity is -20% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Nexstim Oyj's patents?

Nexstim Oyj's patents average 19.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Nexstim Oyj patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Nexstim Oyj

USPTO PatentsView assignee record - 9 granted patents across 5 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nexstim ranks #29,594 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 5 technology areas.

#29,594
of 49,997 US assignees by volume: 31st percentile
by Innovation Score (29.6/100): 19.2
avg claims per patent: -20%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R29594 · Foreign Corporation #29,594 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #29,594/49,997
PHOTO-FINISH New Ideas Manufactur…
CPC-NARROW A61N · 5 areas
INNOV-THIN 29.6/100
CLAIMS-RICH 19.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -20% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: New Ideas Manufacturing LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nexstim’s 29.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (27%) Velocity 2.2 pts (7%) Breadth 7.9 pts (27%) Claim depth 11.5 pts (39%)

Qualcomm Incorporated · highest

85
Nexstim Oyj · this assignee

30
3D Lighting… · lowest

7

What this shows Nexstim's Innovation Score is 29.6/100 (31st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Nexstim?

Each dot is one of Nexstim’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nexstim’s own 19.2 claims/patent is ABOVE the 15.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Nexstim vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nexstim's grants concentrate

Nexstim Oyj is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2017. By volume, Nexstim sits between New Ideas Manufacturing LLC and Nikola Motor Company, LLC.

Nexstim's three-year grant acceleration

Nexstim Oyj shows 2 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

New Ideas Manufac…

9
New Standards Man…

9
Newmarket Pharmac…

9
Newsight Reality

9
Next Issue Media

9
Nfinium Vascular

9
Nightlight Systems

9
Nikola Motor

9
Nexstim Oyj ◀

9

What this shows Nexstim holds 9 patents at rank #29,602, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Nexstim

By rank, the assignees closest to #29,602 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Nexstim's primary technology class.

Nexstim's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 31st percentile higher than 31% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Nexstim Oyj patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	11.1%
2019	4	44.4%
2020	2	22.2%
2022	1	11.1%
2024	1	11.1%

Which technologies does Nexstim Oyj patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 9

A61B - DIAGNOSIS; SURGERY; Identification 5

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

A61G - Transport, Personal Conveyances, OR Accommodation Specially Adapted FOR Patients OR Disabled Persons ; Operating Tables OR CHAIRS; Chairs FOR DENTISTRY; Funeral Devices 1

G01R - Measuring Electric VARIABLES; Measuring Magnetic Variables 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Nexstim Oyj's patent record in context - here's where to go next.

Nexstim Oyj's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #29,594 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Nexstim Oyj against New Ideas Manufacturing LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.